|
Male sex, n (%)
|
37 (74.0)
|
12 (70.6)
|
11 (64.7)
|
14 (87.5)
|
0.277
|
|
Age, years
|
54 ± 14
|
53 ± 14
|
55 ± 15
|
55 ± 15
|
0.499
|
|
Dialysis duration, months
|
20.2 ± 11.6
|
23.4 ± 12.3
|
18.1 ± 9.7
|
18.8 ± 12.5
|
0.213
|
|
Original disease
|
|
DN, n (%)
|
16 (32.0)
|
7 (41.2)
|
6 (35.3)
|
3 (18.8)
|
0.167
|
|
Non-DN, n (%)
|
34 (68.0)
|
10 (58.8)
|
11 (64.7)
|
13 (81.2)
|
|
Blood pressure, mmHg
|
|
Systolic
|
139 ± 14
|
141 ± 11
|
137 ± 18
|
139 ± 13
|
0.845
|
|
Diastolic
|
81 ± 11
|
82 ± 9
|
78 ± 16
|
82 ± 7
|
0.581
|
|
Daily alcohol consumption, n (%)
|
20 (40.0)
|
5 (29.4)
|
8 (47.1)
|
7 (43.8)
|
0.394
|
|
Current smoker, n (%)
|
9 (18.0)
|
3 (17.7)
|
2 (11.8)
|
4 (25.0)
|
0.593
|
|
Past histories of CVD, n (%)
|
8 (16.0)
|
2 (11.8)
|
4 (23.5)
|
2 (12.5)
|
0.939
|
|
History of peritonitis, n (%)
|
8 (16.0)
|
1 (5.9)
|
3 (17.7)
|
4 (25.0)
|
0.133
|
|
Body mass index, kg/m2
|
22.9 ± 2.9
|
22.4 ± 2.4
|
22.1 ± 2.7
|
24.2 ± 3.2
|
0.124
|
|
CTR, %
|
48.2 ± 5.4
|
49.8 ± 4.7
|
48.3 ± 4.6
|
46.6 ± 6.7
|
0.075
|
|
Dialysis modality
|
|
APD, n (%)
|
22 (44.0)
|
11 (64.7)
|
8 (47.1)
|
9 (56.3)
|
0.614
|
|
CAPD, n (%)
|
28 (56.0)
|
6 (35.3)
|
9 (52.9)
|
7 (43.7)
|
|
Use of icodextrin, n (%)
|
41 (82.0)
|
16 (94.1)
|
13 (76.5)
|
12 (75.0)
|
0.150
|
|
Use of HG dialysate, n (%)
|
17 (34.0)
|
11 (64.7)
|
4 (23.5)
|
2 (12.5)
|
0.002
|
|
Dose of ESA, μg/week
|
34 ± 18
|
37 ± 16
|
32 ± 16
|
31 ± 23
|
0.206
|
|
Total Kt/V, /week
|
1.71 ± 0.34
|
1.66 ± 0.42
|
1.61 ± 0.31
|
1.87 ± 0.23
|
0.011
|
|
Renal Kt/V, /week
|
0.46 ± 0.37
|
0.10 ± 0.11
|
0.42 ± 0.18
|
0.88 ± 0.27
|
< 0.001
|
|
Peritoneal Kt/V, /week
|
1.25 ± 0.38
|
1.56 ± 0.41
|
1.19 ± 0.21
|
0.99 ± 0.22
|
< 0.001
|
|
Renal Ccr, L/week, /week
|
29.2 ± 26.9
|
5.1 ± 4.9
|
27.4 ± 8.9
|
56.8 ± 27.8
|
< 0.001
|
|
Urine volume, L/day
|
0.80 ± 0.64
|
0.22 ± 0.24
|
0.76 ± 0.38
|
1.44 ± 0.55
|
< 0.001
|
|
Mean rCUC, L/week/1.73m2
|
22.7 ± 19.4
|
4.2 ± 4.2
|
20.5 ± 6.2
|
44.5 ± 16.5
|
< 0.001
|
|
D/Pcr
|
0.73 ± 0.16
|
0.76 ± 0.16
|
0.72 ± 0.17
|
0.70 ± 0.16
|
0.328
|
|
Prescriptions, n (%)
|
|
RAS inhibitors
|
48 (96.0)
|
17 (100.0)
|
15 (88.2)
|
16 (100)
|
0.972
|
|
Calcium channel blockers
|
37 (74.0)
|
15 (88.2)
|
10 (58.8)
|
12 (75.0)
|
0.370
|
|
β blockers
|
23 (46.0)
|
11 (64.7)
|
6 (35.3)
|
6 (37.5)
|
0.113
|
|
Calcium-containing PBs
|
44 (88.0)
|
13 (76.5)
|
16 (94.1)
|
15 (93.8)
|
0.123
|
|
Non-calcium containing PBs
|
29 (58.0)
|
14 (82.4)
|
6 (35.3)
|
9 (56.3)
|
0.119
|
|
Iron preparations
|
11 (22.5)
|
7 (41.2)
|
2 (11.8)
|
2 (13.3)
|
0.054
|
|
Vitamin D
|
27 (54.0)
|
9 (52.9)
|
7 (41.2)
|
11 (68.8)
|
0.375
|
|
Cinacalcet hydrochloride
|
4 (8.0)
|
1 (5.9)
|
1 (5.9)
|
2 (12.5)
|
0.488
|
